Bhagirathbhai Dholaria, MBBS, on Administering Axi-Cel in the Outpatient Setting for LBCL

Video

The assistant professor of medicine at Vanderbilt University Medical Center discussed results from a retrospective analysis presented at the 2023 Tandem Meetings.

“Our analysis showed that yes, with appropriate safety guards and training and infrastructure, CAR T cell therapy, especially axi-cel, which has highest risk of cytokine release syndrome and neurotoxicity compared to other CD19-directed CAR T cell therapies such as tisa-cel and liso-cel, it can be still safely given.”

Clinicians from University of Vanderbilt investigated outcomes with remote monitoring patients with large B-cell lymphoma treated with axicabtagene ciloleucel (axi-cel; Yescarta) and found that safety and efficacy outcomes were similar between patients treated in inpatient and outpatient settings. Data from the retrospective analysis were presented at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19.

CGTLive spoke with coauthor Bhagirathbhai Dholaria, MBBS, assistant professor of medicine at Vanderbilt University Medical Center, to learn more about the study and the favorable outcomes observed in patients treated in the outpatient setting. He discussed the advantages for both patients and hospitals with outpatient chimeric antigen receptor (CAR) T-cell therapy treatments.

For more coverage of the 2023 Tandem Meetings, click here.

REFERENCE
Akosile TA, Dholaria B, Baer B, et al. The impact of telemedicine and wearable devices in improving the safety profile of outpatient chimeric antigen receptor T-Cell (CAR-T) therapies: A case-control study. Presented at: 2023 Tandem Meetings, February 15-18, Orlando, Florida. Abstract #201
Recent Videos
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Related Content
© 2024 MJH Life Sciences

All rights reserved.